ERAS
Price
$17.89
Change
+$0.03 (+0.17%)
Updated
Aug 14, 12:21 PM (EDT)
Capitalization
6.24B
89 days until earnings call
Intraday BUY SELL Signals
MLTX
Price
$16.51
Change
+$0.01 (+0.06%)
Updated
Aug 14, 01:08 PM (EDT)
Capitalization
1.41B
95 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs MLTX

ERAS vs MLTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ERAS vs. MLTX commentary
Aug 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a StrongBuy and MLTX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 14, 2026
Stock price -- (ERAS: $17.86 vs. MLTX: $16.50)
Brand notoriety: ERAS and MLTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 43% vs. MLTX: 66%
Market capitalization -- ERAS: $6.24B vs. MLTX: $1.41B
ERAS [@Biotechnology] is valued at $6.24B. MLTX’s [@Biotechnology] market capitalization is $1.41B. The market cap for tickers in the [@Biotechnology] industry ranges from $130.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 0 FA rating(s) are green whileMLTX’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 0 green, 5 red.
  • MLTX’s FA Score: 1 green, 4 red.
According to our system of comparison, both ERAS and MLTX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 2 TA indicator(s) are bullish while MLTX’s TA Score has 3 bullish TA indicator(s).

  • ERAS’s TA Score: 2 bullish, 6 bearish.
  • MLTX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, MLTX is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а -2.24% price change this week, while MLTX (@Biotechnology) price change was -8.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.28%. For the same industry, the average monthly price growth was -1.70%, and the average quarterly price growth was +2868.01%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 11, 2026.

MLTX is expected to report earnings on Nov 17, 2026.

Industries' Descriptions

@Biotechnology (+0.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($6.24B) has a higher market cap than MLTX($1.41B). ERAS YTD gains are higher at: 380.108 vs. MLTX (25.190). ERAS has higher annual earnings (EBITDA): -130.68M vs. MLTX (-245.81M). MLTX has more cash in the bank: 358M vs. ERAS (244M). ERAS has less debt than MLTX: ERAS (46M) vs MLTX (101M). ERAS (0) and MLTX (0) have equivalent revenues.
ERASMLTXERAS / MLTX
Capitalization6.24B1.41B444%
EBITDA-130.68M-245.81M53%
Gain YTD380.10825.1901,509%
P/E RatioN/AN/A-
Revenue00-
Total Cash244M358M68%
Total Debt46M101M46%
TECHNICAL ANALYSIS
Technical Analysis
ERASMLTX
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
68%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 8 days ago
85%
Declines
ODDS (%)
Bearish Trend 12 days ago
85%
Bearish Trend 4 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signal:
Gain/Loss:
MLTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TOK156.620.82
+0.52%
iShares MSCI Kokusai ETF
MKAM32.560.12
+0.37%
MKAM ETF
IEMG81.290.27
+0.33%
iShares Core MSCI Emerging Markets ETF
IBTK19.440.04
+0.21%
iShares iBonds Dec 2030 Term Trsry ETF
EMTL42.56N/A
N/A
SPDR DoubleLine Emerging Markets Fixed Income ETF

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with SNGX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then SNGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-3.88%
SNGX - ERAS
42%
Loosely correlated
-2.33%
REPL - ERAS
42%
Loosely correlated
-0.33%
AMLX - ERAS
39%
Loosely correlated
-3.73%
MLTX - ERAS
36%
Loosely correlated
-4.24%
RZLT - ERAS
36%
Loosely correlated
-2.13%
More

MLTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLTX has been closely correlated with KALA. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if MLTX jumps, then KALA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLTX
1D Price
Change %
MLTX100%
-4.24%
KALA - MLTX
82%
Closely correlated
+2.83%
XNCR - MLTX
50%
Loosely correlated
-0.82%
NRIX - MLTX
45%
Loosely correlated
+2.10%
AUPH - MLTX
45%
Loosely correlated
-1.75%
XENE - MLTX
44%
Loosely correlated
-1.58%
More